A detailed history of Allworth Financial LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Allworth Financial LP holds 1,777 shares of BMRN stock, worth $116,677. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,777
Previous 1,968 9.71%
Holding current value
$116,677
Previous $162,000 23.46%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$69.02 - $93.84 $13,182 - $17,923
-191 Reduced 9.71%
1,777 $124,000
Q2 2024

Jul 23, 2024

BUY
$74.43 - $92.22 $297 - $368
4 Added 0.2%
1,968 $162,000
Q1 2024

Apr 25, 2024

BUY
$83.81 - $99.0 $113,981 - $134,640
1,360 Added 225.17%
1,964 $171,000
Q4 2023

Jan 24, 2024

BUY
$76.22 - $98.51 $16,311 - $21,081
214 Added 54.87%
604 $58,000
Q3 2023

Oct 31, 2023

BUY
$85.07 - $94.48 $3,743 - $4,157
44 Added 12.72%
390 $34,000
Q2 2023

Jul 18, 2023

SELL
$86.68 - $100.3 $866 - $1,003
-10 Reduced 2.81%
346 $29,000
Q1 2023

Apr 18, 2023

BUY
$87.74 - $117.27 $11,406 - $15,245
130 Added 57.52%
356 $34,000
Q4 2022

Jan 13, 2023

BUY
$80.93 - $108.63 $2,185 - $2,933
27 Added 13.57%
226 $0
Q3 2022

Oct 18, 2022

BUY
$82.16 - $96.94 $3,204 - $3,780
39 Added 24.38%
199 $17,000
Q2 2022

Jul 13, 2022

SELL
$71.48 - $86.85 $7,290 - $8,858
-102 Reduced 38.93%
160 $13,000
Q3 2021

Nov 02, 2021

BUY
$74.77 - $85.47 $9,421 - $10,769
126 Added 92.65%
262 $20,000
Q2 2021

Aug 02, 2021

SELL
$75.51 - $84.79 $1,887 - $2,119
-25 Reduced 15.53%
136 $11,000
Q1 2021

Apr 29, 2021

BUY
$74.73 - $90.69 $1,569 - $1,904
21 Added 15.0%
161 $12,000
Q3 2020

Nov 03, 2020

BUY
$71.87 - $131.03 $1,796 - $3,275
25 Added 21.74%
140 $11,000
Q4 2019

Jan 16, 2020

BUY
$64.27 - $86.37 $7,391 - $9,932
115 New
115 $10,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.